The Trump administration moved state-licensed medical marijuana products from Schedule I to Schedule III—an FDA-style shift that could lower barriers for research.
The Trump administration has reclassified state-licensed medical marijuana products under the Controlled Substances Act, moving them from Schedule I to Schedule III.
The change. announced on Thursday. removes these products from the federal category reserved for drugs deemed to have “no currently accepted medical use” and a high risk of abuse.. Under the updated classification. the products now sit alongside Schedule III substances such as ketamine and anabolic steroids. which are considered to carry a “moderate to low potential” for dependence.. Federal law still does not legalize marijuana for medical or recreational use nationwide. but the rescheduling can reshape how the drug is regulated—and how quickly evidence is gathered.
Officials framed the decision as part of a broader plan to move cannabis more widely out of Schedule I.. Acting attorney general Todd Blanche said the action is meant to “allow for research on the safety and efficacy” of cannabis so that patients can receive better-informed care and doctors can rely on more consistent evidence.. In parallel. the administration described an “expedited administrative hearing process” aimed at rescheduling cannabis beyond the specific state-licensed products covered by the initial step.
For researchers, the practical impact may be immediate.. Schedule I status has long created extra hurdles for scientific work, including additional paperwork and more expensive safety procedures.. Those requirements did not just slow studies down; they also discouraged some labs from entering the field at all. leaving questions about dosing. long-term effects. and specific medical indications underanswered.. Schedule III. by contrast. generally signals a lower regulatory barrier—meaning studies that were once caught in administrative friction could become easier to launch. expand. or sustain.
There is also a perception shift embedded in the policy language.. Staci Gruber. an associate professor of psychiatry at Harvard Medical School. described the move as “pretty significant” because it acknowledges accepted medical use at the federal level.. That matters culturally as well as scientifically: the Schedule I label has historically carried heavy stigma. influencing how clinicians discuss cannabis and how patients interpret medical claims.. Changing the classification can influence what doctors feel comfortable prescribing and what insurers. researchers. and regulators are willing to treat as legitimate medical questions.
Even so, the new classification comes with boundaries that will shape outcomes in the real world.. The rescheduling applies to state-regulated medical marijuana products rather than establishing full federal legalization.. That distinction is likely to affect where studies can be conducted. what products can be studied. and how institutions manage compliance.. It may also mean that some patients experience changes slower than others. depending on how state programs. clinical practices. and research infrastructures align with federal rules.
The broader push matters beyond laboratories.. Cannabis use intersects with public health concerns ranging from chronic pain management to mental health symptoms. and the federal stance has influenced what kinds of clinical trials are feasible.. If barriers to research ease. scientists may be able to answer questions clinicians often face at the bedside: Which formulations work best for particular conditions?. What are the trade-offs between symptom relief and side effects?. How do effects vary across age groups or across different levels of exposure?
At the same time. the administration linked the rescheduling effort to law-enforcement priorities such as fighting drug cartels and the fentanyl epidemic.. That messaging underscores a key tension in U.S.. drug policy: making space for medical research while maintaining a strong stance against illicit supply and misuse.. Any shift in cannabis scheduling will likely need to coexist with efforts to reduce diversion and protect public health.
Looking ahead. the next step—moving cannabis more broadly from Schedule I to Schedule III—depends on a process described as an expedited administrative hearing.. If that broader rescheduling proceeds, it could accelerate clinical research and potentially improve the reliability of medical guidance.. But researchers and clinicians will still need high-quality trials to determine what benefits are real. for whom they apply. and how risks should be managed.. The schedule change may open doors; it won’t automatically fill them with answers.
In the near term. the biggest takeaway may be less about immediate legalization and more about shifting the environment around evidence.. By reducing federal friction for certain cannabis products. Misryoum expects more studies to become possible—and with that. more clarity on whether cannabis can be integrated into mainstream medicine with the same rigor as other regulated therapies.